|Mr. John P. Walker||Chairman, CEO & Pres||39.52k||N/A||1949|
|Ms. Georgia L. Erbez||Chief Bus. Officer, CFO & Principal Accounting Officer||251k||N/A||1967|
|Dr. Donald J. Kellerman Pharm.D.||VP of Clinical Devel. & Medical Affairs||387.08k||N/A||1955|
|Mr. Eric Scharin||VP of Operations and Engineering||N/A||N/A||1966|
|Dr. Thorsten von Stein M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1962|
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.